Valuing Pharmaceutical Innovation: Pricing and reimbursement for innovative therapies

리서치사	Business Insights
발행일	2008년 07월	상품코드	71272
페이지 정보	121 pages
가격	US $ 3,835 ￦ 4,570,900 PDF by E-mail (Single User License) US $ 14,382 ￦ 17,141,900 PDF by E-mail (Global License)

한글목차
영문목차
관련자료

영문목차

Abstract

Developing, manufacturing and marketing innovative new pharmaceutical drugs is highly complex and involves significant investment. Establishing an acceptable return on investment requires generating sufficient sales revenues which in turn requires maximizing market access at the highest possible price.

Executive Summary

Introduction
Categorizing and valuing innovation
Region and therapy area specific considerations
Pricing challenges for recently launched innovative therapies
Upcoming launches of new innovative therapies

Chapter 1 Introduction

Summary
Introduction
Supply-side factors
Complexity and costs
Market size
Competition
Demand-side factors
Budget
Unmet need
Competition
Valuing innovation

Chapter 2 Categorizing and valuing innovation

Summary
Introduction
Categories of innovations
New market innovations
Redefining the category innovations
Second generation innovations
Incremental therapeutic innovations
Incremental formulation innovations
Innovative market access strategies
Orphan drugs
Risk-sharing

Chapter 3 Region and therapy area specific considerations

Summary
Introduction
Approaches to market access in major markets
USA
Japan
France
Germany
Italy
Spain
UK
Therapy area markets for innovative therapies
Oncology
HIV
Autoimmune diseases
Diabetes
Others

Chapter 4 Pricing challenges of recently launched innovative therapies

Summary
Introduction
New market innovations
Gardasil (human papilloma virus vaccine): changing the treatment algorithm
Lysosomal storage diseases: pricing versus patient weight
Redefining the category innovations
Chantix (varenicline): redefining a therapeutic category
Nexavar (sorafenib) versus Sutent (sunitinib): meeting an unmet need
Second generation innovations
Lyrica (pregabalin): a new, improved neuropathic pain drug
Macugen vs Lucentis vs Avastin : premium pricing against off-label use
Incremental therapeutic innovations
Byetta vs Januvia: changing the treatment paradigm for type 2 diabetes
Prezista vs Fuzeon: premium pricing in HIV/AIDS
Incremental formulation innovations
Abraxane (paclitaxel): pricing incremental convenience
Vivitrol: market access vs premium pricing

Chapter 5 Upcoming launches of new innovative therapies

Summary
Introduction
New market innovations
Lupuzor (IPP-201101) - ImmuPharma
Sinunase - Accentia
Redefining the category innovations
Bapineuzumab - Elan/Wyeth
Multikine - CelSci
Second generation innovations
Arzoxifene - Eli Lilly
Cordaptive (niacin ER/laropiprant) - Merck
Incremental therapeutic innovations
Naproxcinod - NicOx
RhuDex - MediGene
Incremental formulation innovations
Denosumab - Amgen
Xarelto (rivaroxaban) - Bayer/J&J
Chapter 6 Appendix
Research sources
Pricing data

List of Figures

Figure 1.1: Supply and demand factors impacting market access for innovative therapies
Figure 2.2: Innovative drug categories by level of innovation and ease of market access
Figure 3.3: Source of prescription drug expenditures in the US, 2005-2006
Figure 3.4: Italian categorization for innovative new therapies
Figure 4.5: Gardasil global sales, 2006-07 ($m)
Figure 4.6: Selected lysosomal storage disease drugs global sales, 2006-07
Figure 4.7: Selected lysosomal storage disease drugs pricing in the UK and US, 2008
Figure 4.8: Smoking cessation drugs global sales, 2006-07
Figure 4.9: Smoking cessation drugs pricing in the UK and US, 2008
Figure 4.10: Nexavar and Sutent global sales, 2006-07
Figure 4.11: Nexavar and Sutent pricing in the UK and US, 2008
Figure 4.12: Selected neuropathic pain drugs global sales, 2006-07
Figure 4.13: Selected neuropathic pain drugs pricing in the UK and US, 2008
Figure 4.14: Age-related macular degeneration drugs global sales, 2006-07
Figure 4.15: Age-related macular degeneration drugs pricing in the UK and US, 2008
Figure 4.16: Selected type 2 diabetes drugs global sales, 2006-07
Figure 4.17: Selected type 2 diabetes drugs pricing in the UK and US, 2008
Figure 4.18: Selected HIV/AIDS drugs global sales, 2006-07
Figure 4.19: Selected HIV/AIDS drugs pricing in the UK and US, 2008
Figure 4.20: Taxane drugs global sales, 2006-07
Figure 4.21: Taxane drugs pricing in the US, 2008
Figure 4.22: Alcohol dependency drugs global sales, 2006-07
Figure 4.23: Alcohol dependency drugs pricing in the US, 2008

List of Tables

Table 3.1: Classification for price premium (Japanese healthcare system)
Table 4.2: Gardasil pricing in the UK and US, 2008
Table 4.3: Selected lysosomal storage disease drugs pricing in the UK and US, 2008
Table 4.4: Smoking cessation drugs pricing in the UK and US, 2008
Table 4.5: Nexavar and Sutent pricing in the UK and US, 2008
Table 4.6: Selected neuropathic pain drugs pricing in the UK and US, 2008
Table 4.7: Age-related macular degeneration drugs pricing in the UK and US, 2008
Table 4.8: Selected type 2 diabetes drugs pricing in the UK and US, 2008
Table 4.9: Selected HIV/AIDS drugs pricing in the UK and US, 2008
Table 4.10: Taxane drugs pricing in the UK and US, 2008
Table 4.11: Alcohol dependency drugs pricing in the UK and US, 2008
Table 5.12: Selected innovative therapies currently in late stage development
Table 6.13: Key UK and US pricing data for leading case studies, 2008
Table 6.13: Key UK and US pricing data for leading case studies, 2008 (continued)